GET DAILY SIGNALSWhy Is Nanobiotix (NBTX) Stock Down -0.3% Today?
Key Takeaways
- NBTX shares eased about 0.3% to $32.77, down from a prior close of $32.87.
- No single company-specific catalyst drove the move; the decline reflects modest profit-taking after a strong prior session.
- The pullback follows a roughly 2.6% advance in the previous trading session, suggesting routine consolidation rather than a fundamental shift.
- Light trading volume amplified normal day-to-day volatility in this thinly traded, small-cap biotech name.
- Management is scheduled to present at the Jefferies Global Healthcare Conference (Nov. 16) and the UBS Global Biopharma Conference (Nov. 17).
- Traders are watching for any clinical or partnership updates around the company's lead candidate, NBTXR3, and broader biotech sentiment.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages.
- To see how automated systems are positioning across the market, visit Trending AI Robots.
Opening Summary
Nanobiotix S.A. (NBTX) is a Paris-headquartered, late-clinical-stage biotechnology company pioneering physics-based nanotherapeutics for cancer and other serious diseases. Its lead asset, NBTXR3 (also known as JNJ-1900), is being developed in collaboration with Johnson & Johnson. In today's session, the company's American Depositary Shares slipped about 0.3%, trading near $32.77 compared with a prior close of $32.87. The modest decline came on subdued volume and without any major company-specific headline, leaving markets to attribute the move to routine profit-taking and broader sector drift rather than a change in the company's fundamentals.
Profit-Taking After a Recent Rally
The most straightforward explanation for today's dip is simple consolidation. NBTX shares advanced roughly 2.6% in the prior session and have been volatile in recent weeks as investors repositioned around the stock. After a run-up, some short-term traders typically lock in gains, and a fractional pullback of less than half a percent is consistent with healthy digestion of recent gains rather than a bearish fundamental catalyst. The stock remains well off its recent lows, underscoring that today's move is incremental rather than directional.
Thin Volume and Small-Cap Volatility
As a relatively small-cap, clinical-stage biotechnology name, NBTX is prone to outsized intraday swings on light trading volume. Recent sessions have seen notably lower-than-average activity, a condition that can magnify even minor shifts in supply and demand. With no earnings release or regulatory event scheduled today, the price action appears driven primarily by the technical ebb and flow of a thinly traded stock rather than by new information.
Company News and Upcoming Catalysts
Earlier this week, Nanobiotix announced that Chief Executive Officer Laurent Levy and Chief Financial Officer Arnd Christ will participate in two investor conferences in mid-November: the Jefferies Global Healthcare Conference in London on Nov. 16 and the UBS Global Biopharma Conference on Nov. 17. While these events can serve as venues for clinical and strategic updates, the announcements themselves have already been made and were not new to the market today. Investors are nonetheless watching these appearances for any incremental commentary on the NBTXR3 development program and its path toward broader regulatory and commercial milestones.
Market Context and Trading Activity
The broader biotech and small-cap universe has shown mixed momentum recently, and NBTX has largely tracked its own idiosyncratic catalyst cycle rather than moving in lockstep with major indices. Trading activity today remained light, consistent with the pattern of recent sessions and reflecting limited institutional conviction in either direction. With no clear macro shock or sector-wide driver, the fractional decline is best understood as a pause rather than a reversal, and key technical levels remain largely intact following the prior session's advance.
What Comes Next for NBTX
Looking ahead, market participants will focus on the upcoming investor conference presentations and any updates on the company's lead oncology candidate, NBTXR3, as well as the status of its collaboration with Johnson & Johnson. Clinical data readouts, regulatory milestones, and partnership developments remain the primary drivers of sentiment for this late-stage biotech. Broader market conditions and investor appetite for speculative, pre-profitability healthcare names will also shape near-term trading. As with all clinical-stage biotech companies, risks include clinical setbacks, regulatory delays, and financing requirements, all of which can produce sharp moves in either direction.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, but only the strongest performers are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to discover automated approaches that may align with your own market outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBTX in upward trend: price rose above 50-day moving average on November 09, 2026
NBTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +7.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 53 cases where NBTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.498). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement